Abivax Shares Surge 11.7% in a Week Ahead of Annual Results

Abivax's Stock Crosses Key Moving Averages

Abivax's stock price has risen above its 20-day and 50-day moving averages, located at €103.07 and €102.18 respectively, after testing them lower in recent weeks. This crossing represents a short-term recovery signal, especially since the stock remains far from its 200-day moving average, set at €73.27, indicating the strength of the long-term upward trend. The RSI, at 39, remains close to the oversold zone, suggesting that the stock had potential for a mechanical rebound after recent consolidation. The most relevant support threshold is at €93.70, a level that was not threatened during the correction. Resistance to watch is set at €112.40, close to the upper limit of the Bollinger Bands, set at €114.44. Breaking through this zone could pave the way for a new phase of appreciation. The one-month volatility remains contained at 13.80, while the negative beta of -0.54 confirms the stock's decorrelation from the overall Paris market.

French Biotech Set to Publish 2025 Annual Results

The French biotech company, specializing in the development of treatments for chronic inflammatory diseases, is set to publish its 2025 annual results on March 23, exactly one week from now. This deadline is the next identified catalyst for the stock, which has shown a spectacular performance of 1,823% over the past year, reflecting the market's evolving perception of its clinical pipeline. Over three months, the progress remains modest at 0.77%, indicating that the stock has undergone a stabilization phase after its strong rise. The market context remains marked by high tension, with the VIX last quoted at 27.29 on March 12, up 12.63% for the session. In the Paris-listed healthcare sector, Sanofi was up 0.17% in Monday's session, in a generally cautious environment. Abivax's upcoming financial milestones include the publication of the first quarter 2026 results on June 1, followed by the semi-annual accounts on September 14.